Search

Author/Creator Oliver, R.

3. Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study. (27th December 2021)

Authors:
Oliver, R.; Krueger, J.G.; Glatt, S.; Vajjah, P.; Mistry, C.; Page, M.; Edwards, H.; Garcet, S.; Li, X.; Dizier, B.; Maroof, A.; Watling, M.; el Baghdady, A.; Baeten, D.; Ionescu, L.; Shaw, S.
Journal:
British journal of dermatology
Issue:
Volume 186:Number 4(2022)
Page Start:
652
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study. (1st April 2022)

Authors:
Oliver, R.; Krueger, J.G.; Glatt, S.; Vajjah, P.; Mistry, C.; Page, M.; Edwards, H.; Garcet, S.; Li, X.; Dizier, B.; Maroof, A.; Watling, M.; el Baghdady, A.; Baeten, D.; Ionescu, L.; Shaw, S.
Journal:
British journal of dermatology
Issue:
Volume 186:Number 4(2022)
Page Start:
652
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Impact of intended and relative dose intensity of R‐CHOP in a large, consecutive cohort of elderly diffuse large B‐cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age. (11th April 2019)

Authors:
Eyre, T. A.; Martinez‐Calle, N.; Hildyard, C.; Eyre, D. W.; Plaschkes, H.; Griffith, J.; Wolf, J.; Fields, P.; Gunawan, A.; Oliver, R.; Djebbari, F.; Booth, S.; McMillan, A.; Fox, C. P.; Bishton, M. J.; Collins, G. P.; Hatton, C. S. R.
Journal:
Journal of internal medicine
Issue:
Volume 285:Number 6(2019)
Page Start:
681
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗